Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267

Benzinga Newsdesk www.benzinga.com Negative 72.9%

Neg 72.9% Neu 0% Pos 0%

Deutsche Bank analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $280 to $267.